Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 08, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 08, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg.".